Skip to main content

Market Overview

Protalix's PRX–102 Monthly Treatment Shows Benefit In Fabry Disease

  • Protalix BioTherapeutics Inc (NYSE: PLX) and its collaborating partner Chiesi Farmaceutici S.p.A. announced positive topline results from the BRIGHT Phase 3 trial evaluating pegunigalsidase alfa (PRX–102) for the potential treatment of Fabry disease.
  • It is a genetic disorder in which the body cannot make an enzyme called alpha-galactosidase A, which is essential to breaking down globotriaosylceramide (Gb3 or GL-3), a type of fat that cells can use as building blocks.
  • PRX–102 is a plant cell-expressed recombinant, PEGylated, cross-linked α–galactosidase–A product candidate that is, administered every four weeks.
  • Results indicated that intravenous infusion of PRX–102 was well-tolerated, and stable clinical presentation was maintained. 
  • No new patients developed treatment-induced anti-drug antibodies following the switch to PRX–102 treatment.
  • Study outcome measures showed plasma lyso–Gb3 concentrations remained stable during the study with a mean change of 3.01 nM from baseline to Week 52.
  • Mean absolute change of eGFR values were stable during the 52–week treatment period, with a mean change from baseline of –1.27 mL/min/1.73 m2.
  • The company will report final data from the study in the second half of 2021
  • Price Action: PLX increased 7.2% at $5.54 in premarket trading on the last check Tuesday.

Related Articles (PLX)

View Comments and Join the Discussion!

Posted-In: Fabry diseaseBiotech News FDA General

Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Everything you need to know about the latest SPAC news.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at